This definition appears rarely
See other definitions of SSRI
Samples in periodicals archive:
Crazymeds’ Manifesto > MedClass > Antidepressants > Serotonin-Selective Reuptake Inhibitor.
fluvoxamine Neuropharmacology An antidepressant that blocks serotonin reuptake at the synapse, approved for managing OCD. See Obsessive-compulsive disorder, Serotonin-selective reuptake inhibitor.
2009. 08083. PMID 19289334. ^ Leo RJ (1996). "Movement disorders associated with the serotonin selective reuptake inhibitors". The Journal of Clinical Psychiatry 57 (10): 449–54. doi:10. 4088/JCP. v57n1002. PMID 8909330.
Benedict, A; Arellano, J; De Cock, E; Baird, J (2010). "Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland". Journal of Affective Disorders 120 (1–3): 94–104. doi:10. 1016/j. jad. 2009.
Review:Leo RJ (1996). "Movement disorders associated with the serotonin selective reuptake inhibitors". The Journal of Clinical Psychiatry57 (10): 449–54. doi:10. 4088/JCP. v57n1002. PMID 8909330.
Venlafaxine has also shown promise in treating rigorously defined treatment-refractory depression. The adverse effects of venlafaxine that most often led to discontinuation from a clinical study were nausea (6%), somnolence (3%), insomnia (3%), and dizziness (3%). Although nausea was the most common adverse effect overall, it resolved rapidly--within the first 1 to 3 weeks of therapy. Other adverse events with incidences significantly higher than with placebo were dizziness, constipation, sweating, nervousness, and abnormal ejaculation. The seizure rate and potential for cardiac conduction changes or orthostatic hypotension with venlafaxine were comparable with rates seen with the serotonin selective reuptake inhibitors.
Potency and selectivity are fundamental pharmacological concepts essential to understanding the basic neuropharmacology and the clinical psychopharmacology of serotonin selective reuptake inhibitors.